Melinta Therapeutics announced new data regarding Baxdela (delafloxacin) activity against fluorquinolone-susceptible and fluoroquinolone-resistant Staphylococcus aureus isolates. The full findings were published in Antimicrobial Agents and Chemotherapy.
The analysis included study patients from the Phase 3 PROCEED trial. Treatment with Baxdela resulted in high response rates against fluoroquinolone-resistant bugs, eradicating levofloxacin-non-susceptible S aureus infections in 98.8% of evaluable cases, and levofloxacin-non-susceptible methicillin-resistant S aureus infections in 98.6% of evaluable cases.
Baxdela also yielded high response rates against S aureus isolates with mutations in the Quinolone Resistance Determining Region (QRDR) in 98.8% of cases. QRDR mutations lower the fluoroquinolone binding and increase resistance.
Baxdela, a fluoroquinolone antibiotic, was approved for the treatment of acute bacterial skin & skin structure infections (ABSSSI). It is currently being evaluated in patients with community-acquired bacterial pneumonia (CABP). Baxdela for injection is supplied as a sterile, lyophilized powder in 300mg single-dose vials. The oral tablets are available in a 450mg strength in 20-count bottles.
Baxdela™ [package insert]. New Haven, Connecticut: Melinta Therapeutics; 2017
This article originally appeared on MPR